---
title: "Ascendis Pharma sells priority review voucher for $187.5 million cash"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290103981.md"
description: "Ascendis Pharma sold its Rare Pediatric Disease Priority Review Voucher for $187.5 million in cash. The transaction closed on June 17, 2026, with proceeds reported before expenses. The voucher was awarded by the FDA following the February 2026 approval of YUVIWEL (navepegritide)."
datetime: "2026-06-17T20:48:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290103981.md)
  - [en](https://longbridge.com/en/news/290103981.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290103981.md)
---

# Ascendis Pharma sells priority review voucher for $187.5 million cash

-   Ascendis Pharma completed the sale of its Rare Pediatric Disease Priority Review Voucher to an undisclosed buyer for USD 187.5 million cash. \* Transaction closed June 17, 2026; proceeds reported before transaction-related expenses. \* The voucher was awarded by the FDA following the February 2026 approval of YUVIWEL (navepegritide). Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-274306), on June 17, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)

## Related News & Research

- [Ascendis Pharma (ASND) Says 104 Week TransCon CNP Data Still Looks Strong](https://longbridge.com/en/news/292392728.md)
- [Bank of New York Mellon Corp Reduces Stock Position in Ascendis Pharma A/S $ASND](https://longbridge.com/en/news/293716720.md)
- [B Capital invests in pediatric behavioral health provider Flourish Health](https://longbridge.com/en/news/294365281.md)
- [Marks Group Wealth Management Inc Purchases New Shares in Ascendis Pharma A/S $ASND](https://longbridge.com/en/news/293016157.md)
- [Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall?](https://longbridge.com/en/news/294229928.md)